SERUM THROMBOPOIETIN LEVELS IN PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY WITH SUPPORT OF PURIFIED PERIPHERAL-BLOOD CD34+ CELLS

In a case control study, serum levels of thrombopoietin (TPO) were det ermined by a sandwich ELISA in 20 patients (median age, 7 years; range , 2-56 years) with various malignancies who received high-dose chemoth erapy and a stem cell rescue operation, The patients received two diff erent transplant modalities: (a) 12 patients received purified autolog ous peripheral blood CD34+ cells; and (b) 8 patients received cells in the CD34(-) fraction, which still. contains many CD34+ cells, No sign ificant differences were observed between the two groups with regard t o the duration required to achieve an absolute granulocyte count of >0 .5 x 10(9)/ liter, the duration of dependence on platelet transfusion, or the number of platelet transfusions, In both groups, the serum TPO levels were inversely correlated with the circulating platelet count. Multivariate analysis demonstrated that significant determinants of t he serum TPO level included the circulating platelet count (standardiz ed regression coefficient = -0.5179), transplantation with cells in th e CD34(-) fraction (0.2414), solid tumor (0.1420), and the age of the patient (-0.1236; r(2) = 0.3021; P < 0.0001), These results suggest th at the mode of stem cell support (ie., the presence of accessory cells in the inoculum), age, or the type of preceding chemotherapy affects serum TPO levels after transplantation.